This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64. 10.1038/nrc3239PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212252–6410.1038/nrc3239Open DOISearch in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEet alNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373123–3510.1056/NEJMoa1504627Open DOISearch in Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627–3910.1056/NEJMoa1507643Open DOISearch in Google Scholar
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824GaronEBRizviNAHuiRLeighlNBalmanoukianASEderJPet alPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med20153722018–2810.1056/NEJMoa1501824Open DOISearch in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAet alPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823–3310.1056/NEJMoa1606774Open DOISearch in Google Scholar
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20. 10.1158/1078-0432.CCR-09-1624.WolchokJDHoosAO’DaySWeberJSHamidOLebbéCet alGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res2009157412–2010.1158/1078-0432.CCR-09-1624Open DOISearch in Google Scholar
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. 10.1016/S14702045(17)30074-8SeymourLBogaertsJPerroneAFordRSchwartzLHMandrekarSet aliRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet Oncol201718e143–5210.1016/S14702045(17)30074-8Open DOISearch in Google Scholar
Hodi FS, Hwu WJ, Kefford R. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510-7. 10.1200/JCO.2015.64.0391HodiFSHwuWJKeffordR.Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumabJ Clin Oncol2016341510–710.1200/JCO.2015.64.0391Open DOISearch in Google Scholar
Kurra V, Sullivan RJ, Gainor JF, Hodi FS, Gandhi L, Sadow CA, et al. Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. [abstract]. J Clin Oncol 2016; 34(15 Suppl): No. 6580. 10.1200/JCO.2016.34.15_suppl.6580KurraVSullivanRJGainorJFHodiFSGandhiLSadowCAet alPseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. [abstract]J Clin Oncol201634(15 Suppl): No658010.1200/JCO.2016.34.15_suppl.6580Open DOISearch in Google Scholar
Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB 2nd, et al. Thoracic imaging of non-small cell lung cancer treated with antiprogrammed death receptor-1 therapy. Curr Prob Diagn Radiol 2018 [Epub ahead of print]. 10.1067/j.cpradiol.2018.01.005HammerMBagleySAggarwalCBaumlJNachiappanACSimoneCB 2ndet alThoracic imaging of non-small cell lung cancer treated with antiprogrammed death receptor-1 therapyCurr Prob Diagn Radiol2018[Epub ahead of print]. doi: 10.1067/j.cpradiol.2018.01.005Open DOISearch in Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627–3910.1056/NEJMoa1507643Open DOISearch in Google Scholar
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-12. 10.1200/JCO.2014.58.3708GettingerSNHornLGandhiLSpigelDRAntoniaSJRizviNAet alOverall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol2015332004–1210.1200/JCO.2014.58.3708Open DOISearch in Google Scholar
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541-3. 10.1200/JCO.2015.61.6870ChiouVLBurottoM.Pseudoprogression and immune-related response in solid tumorsJ Clin Oncol2015333541–310.1200/JCO.2015.61.6870Open DOISearch in Google Scholar
Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016; 4: 84. 10.1186/s40425-016-0193-2NishinoMRamaiyaNHChambersESAdeniAEHatabuHJännePAet alImmune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patientsJ Immunother Cancer201648410.1186/s40425-016-0193-2Open DOISearch in Google Scholar
Kim HK, Heo MH, Lee HS, Sun JM, Lee SH, Ahn JS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol 2017; 80: 591-8. 10.1007/s00280-017-3396-4KimHKHeoMHLeeHSSunJMLeeSHAhnJSet alComparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitorsCancer Chemother Pharmacol201780591–810.1007/s00280-017-3396-4Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRet alNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945228–4710.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar
Sarfaty M, Moore A, Dudnik E, Peled N. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case report. Medicine (Baltimore) 2017; 96: e5951. 10.1097/MD.0000000000005951SarfatyMMooreADudnikEPeledN.Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case reportMedicine (Baltimore)201796e595110.1097/MD.0000000000005951Open DOISearch in Google Scholar
Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two cases. J Immunother Cancer 2016 4: 80. 10.1186/s40425-016-0185-2KollaBCPatelMR.Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two casesJ Immunother Cancer201648010.1186/s40425-016-0185-2Open DOISearch in Google Scholar
Izumida T, Kawagishi Y, Tsuji H. Pseudoprogression in lung adenocarcinoma during treatment with nivolumab. BMJ Case Reports 2017; doi:10.1136/ bcr-2017-219919. [cited 2018 Feb 2]. Available at http://casereports.bmj.com/content/2017/bcr-2017-219919.fullIzumidaTKawagishiYTsujiH.Pseudoprogression in lung adenocarcinoma during treatment with nivolumabBMJ Case Reports2017doi:10.1136/ bcr-2017-219919. [cited 2018 Feb 2]. Available athttp://casereports.bmj.com/content/2017/bcr-2017-219919.full10.1136/bcr-2017-219919Search in Google Scholar
Kumagai T, Kimura M, Inoue T, Tamiya M, Nishino K, Imamura F. Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. Thorac Cancer 2017; 8: 275-7. 10.1111/1759-7714.12431KumagaiTKimuraMInoueTTamiyaMNishinoKImamuraF.Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatmentThorac Cancer20178275–710.1111/1759-7714.12431Open DOISearch in Google Scholar
Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer 2017; 113: 4-6. 10.1016/j.lungcan.2017.08.020HochmairMJSchwabSBurghuberOCKrenbekDProschH.Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapyLung Cancer20171134–610.1016/j.lungcan.2017.08.020Open DOISearch in Google Scholar
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565-70. 10.1126/science.1203486SchreiberRDOldLJSmythMJ.Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotionScience20113311565–7010.1126/science.1203486Open DOISearch in Google Scholar
Garon EB, Naiyer AR, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824GaronEBNaiyerARHuiRLeighlNBalmanoukianASEderJPet alPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med20153722018–2810.1056/NEJMoa1501824Open DOISearch in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627BrahmerJReckampKLBaasPCrinòLEberhardtWEEPoddubskayaEet alNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373123–3510.1056/NEJMoa1504627Open DOISearch in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAet alPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823–3310.1056/NEJMoa1606774Open DOISearch in Google Scholar
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65. 10.1016/S01406736(16)32517-XRittmeyerABarlesiFWaterkampDParkKCiardielloFvonPawel Jet alAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet2017389255–6510.1016/S01406736(16)32517-XOpen DOISearch in Google Scholar
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. 10.1016/S0140-6736(16)00587-0FehrenbacherLSpiraABallingerMKowanetzMVansteenkisteJMazieresJet alAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trialLancet20163871837–4610.1016/S0140-6736(16)00587-0Open DOISearch in Google Scholar
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-smallcell lung cancer (BIRCH). J Clin Oncol 2017; 35: 2781-9. 10.1200/ JCO.2016.71.9476PetersSGettingerSJohnsonMLJännePAGarassinoMCChristophDet alPhase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-smallcell lung cancer (BIRCH)J Clin Oncol2017352781–910.1200/JCO.2016.71.9476Open DOISearch in Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. 10.1016/j.cell.2011.02.013HanahanDWeinbergRA.Hallmarks of cancer: the next generationCell2011144646–7410.1016/j.cell.2011.02.013Open DOISearch in Google Scholar
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Re Oncol Hematol 2013; 88: 218-30. 10.1016/j.critrevonc.2013.03.010GuthrieGJCharlesKARoxburghCSHorganPGMcMillanDCClarkeSJ.The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancerCrit Re Oncol Hematol201388218–3010.1016/j.critrevonc.2013.03.010Open DOISearch in Google Scholar
Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111: 452-60. 10.1038/bjc.2014.317KangMHGoSISongHNLeeAKimSHKangJHet alThe prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancerBr J Cancer2014111452–6010.1038/bjc.2014.317Open DOISearch in Google Scholar
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124. 10.1093/jnci/dju124TempletonAJMcNamaraMGŠerugaBVera-BadilloFEAnejaPOcañaAet alPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisJ Natl Cancer Inst2014106dju12410.1093/jnci/dju124Open DOISearch in Google Scholar
Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 2017; 106: 1-7. 10.1016/j.lungcan.2017.01.013BagleySJKothariSAggarwalCBaumlJMAlleyEWEvansTLet alPretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer20171061–710.1016/j.lungcan.2017.01.013Open DOISearch in Google Scholar
Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015; 112: 1904-10. 10.1038/bjc.2015.180FerrucciPFGandiniSBattagliaAAlfieriSDiGiacomo AMGiannarelliDet alBaseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patientsBr J Cancer20151121904–1010.1038/bjc.2015.180Open DOISearch in Google Scholar
Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients aſter chemoradiotherapy. Neoplasma 2018; 59: 101-6. 10.4149/ neo_2018_170206N77VrankarMZwitterMKernIStanicK.PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients aſter chemoradiotherapyNeoplasma201859101–610.4149/neo_2018_170206N77Open DOISearch in Google Scholar
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysis. Eur J Surg Oncol 2015; 41: 450-6. doi:10.1016/j.ejso.2015.01.020WangAWangHYLiuYZhaoMCZhangHJLuZYet alThe prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysisEur J Surg Oncol201541450–6doi:10.1016/j.ejso.2015.01.02010.1016/j.ejso.2015.01.020Search in Google Scholar
Zhou Z, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer : a meta-analysis. Transl Lung Cancer Res 2015; 4: 203-8. 10.3978/j.issn.2218-6751.2015.03.02ZhouZZhanPSongY.PD-L1 over-expression and survival in patients with non-small cell lung cancer : a meta-analysisTransl Lung Cancer Res20154203–810.3978/j.issn.2218-6751.2015.03.02Open DOISearch in Google Scholar
Saba L, Poreu M, Schmid B, Flohr T. Dual energy CT: basic principles. In: Cecco CN, Laghi A, Schoepf UJ, Meinel FG, editors. Dual energy CT in oncology Cham, Germany: Springer. p. 1-20.SabaLPoreuMSchmidBFlohrT.Dual energy CT: basic principles. In: Cecco CN, Laghi A, Schoepf UJ, Meinel FG, editorsDual energy CT in oncologyCham, GermanySpringerp1–2010.1007/978-3-319-19563-6_1Search in Google Scholar
Bensch F, Veen E, Jorritsma A. First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab. Paper presented at: AACR Annual Meeting, Washington Convention Center, April 2, 2017. CT017.BenschFVeenEJorritsmaA.First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab. Paper presented at: AACR Annual MeetingWashington Convention CenterApril22017CT01710.1158/1538-7445.AM2017-CT017Search in Google Scholar
